Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Monday. The firm issued a sell rating on the stock.

Bio-Path Trading Down 6.4 %

Shares of Bio-Path stock opened at $0.17 on Monday. Bio-Path has a twelve month low of $0.12 and a twelve month high of $7.67. The company has a 50-day simple moving average of $0.66 and a two-hundred day simple moving average of $0.84.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.